Cargando…
Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis
The highly contagious coronavirus, which had already affected more than 2 million people in 210 countries, triggered a colossal economic crisis consequently resulting from measures adopted by various goverments to limit transmission. This has placed the lives of many people infected worldwide at gre...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481067/ https://www.ncbi.nlm.nih.gov/pubmed/33254559 http://dx.doi.org/10.1016/j.mehy.2020.110254 |
_version_ | 1783580525247594496 |
---|---|
author | Mehta, Meenu Prasher, Parteek Sharma, Mousmee Shastri, Madhur D. Khurana, Navneet Vyas, Manish Dureja, Harish Gupta, Gaurav Anand, Krishnan Satija, Saurabh Chellappan, Dinesh Kumar Dua, Kamal |
author_facet | Mehta, Meenu Prasher, Parteek Sharma, Mousmee Shastri, Madhur D. Khurana, Navneet Vyas, Manish Dureja, Harish Gupta, Gaurav Anand, Krishnan Satija, Saurabh Chellappan, Dinesh Kumar Dua, Kamal |
author_sort | Mehta, Meenu |
collection | PubMed |
description | The highly contagious coronavirus, which had already affected more than 2 million people in 210 countries, triggered a colossal economic crisis consequently resulting from measures adopted by various goverments to limit transmission. This has placed the lives of many people infected worldwide at great risk. Currently there are no established or validated treatments for COVID-19, that is approved worldwide. Nanocarriers may offer a wide range of applications that could be developed into risk-free approaches for successful therapeutic strategies that may lead to immunisation against the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) which is the primary causative organism that had led to the current COVID-19 pandemic. We address existing as well as emerging therapeutic and prophylactic approaches that may enable us to effectively combat this pandemic, and also may help to identify the key areas where nano-scientists can step in. |
format | Online Article Text |
id | pubmed-7481067 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74810672020-09-10 Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis Mehta, Meenu Prasher, Parteek Sharma, Mousmee Shastri, Madhur D. Khurana, Navneet Vyas, Manish Dureja, Harish Gupta, Gaurav Anand, Krishnan Satija, Saurabh Chellappan, Dinesh Kumar Dua, Kamal Med Hypotheses Article The highly contagious coronavirus, which had already affected more than 2 million people in 210 countries, triggered a colossal economic crisis consequently resulting from measures adopted by various goverments to limit transmission. This has placed the lives of many people infected worldwide at great risk. Currently there are no established or validated treatments for COVID-19, that is approved worldwide. Nanocarriers may offer a wide range of applications that could be developed into risk-free approaches for successful therapeutic strategies that may lead to immunisation against the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) which is the primary causative organism that had led to the current COVID-19 pandemic. We address existing as well as emerging therapeutic and prophylactic approaches that may enable us to effectively combat this pandemic, and also may help to identify the key areas where nano-scientists can step in. Elsevier Ltd. 2020-11 2020-09-10 /pmc/articles/PMC7481067/ /pubmed/33254559 http://dx.doi.org/10.1016/j.mehy.2020.110254 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Mehta, Meenu Prasher, Parteek Sharma, Mousmee Shastri, Madhur D. Khurana, Navneet Vyas, Manish Dureja, Harish Gupta, Gaurav Anand, Krishnan Satija, Saurabh Chellappan, Dinesh Kumar Dua, Kamal Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis |
title | Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis |
title_full | Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis |
title_fullStr | Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis |
title_full_unstemmed | Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis |
title_short | Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis |
title_sort | advanced drug delivery systems can assist in targeting coronavirus disease (covid-19): a hypothesis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481067/ https://www.ncbi.nlm.nih.gov/pubmed/33254559 http://dx.doi.org/10.1016/j.mehy.2020.110254 |
work_keys_str_mv | AT mehtameenu advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT prasherparteek advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT sharmamousmee advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT shastrimadhurd advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT khurananavneet advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT vyasmanish advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT durejaharish advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT guptagaurav advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT anandkrishnan advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT satijasaurabh advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT chellappandineshkumar advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis AT duakamal advanceddrugdeliverysystemscanassistintargetingcoronavirusdiseasecovid19ahypothesis |